Cookie Consent
By clicking “Accept”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.
Women’s health remains one of the most underserved areas in clinical research, with significant unmet medical needs. For over 25 years, SCOPE has been at the forefront of conducting clinical trials in this field, improving drug and device therapies for reproductive health, age-related conditions, and other critical indications. Our expertise, combined with strong partnerships with experienced investigators and key opinion leaders, ensures that we meet recruitment and treatment goals — on time and within budget.
SCOPE is a globally operating Contract Research Organization (CRO) with a proven track record in delivering high-quality Phase I–IV clinical trials across all major therapeutic areas. Our expertise extends to pediatric trials, orphan drugs, biologics, medical devices, non-interventional studies (NIS), and post-authorization studies. Since 2000, we have successfully conducted over 300 studies involving more than 88,000 patients worldwide. With offices in 11 countries across Europe, our 200 permanent employees support clinical trials in over 30 countries, covering all major markets.
Partner with a CRO that combines global reach, deep expertise, and a commitment to delivering high-quality clinical research solutions.
By utilizing more than two decades of industry experience, coupled with the professional experience of our staff, SCOPE provides a well-established approach for successful Women’s Health trials.
Here’s what sets us apart:
Recruitment is pivotal in achieving the desired outcome of a study. The SCOPE team is highly experienced in developing therapeutically appropriate and insightful feasibility questionnaires and extrapolating this to our enrollment plans. Our teams recognize that feminine healthcare has considerable variability in different settings across countries and local cultures, thereby requiring sensitivity and local knowledge. SCOPE therefore conducts a feasibility survey to confirm projected recruitment rates and utilizes feedback from local Principal Investigators (PI) as part of our standard proposal process.
SCOPE project teams are experts in the design and delivery of site training to ensure protocol-consistent enrollment and efficacy assessments, using electronic data capture systems (EDC, eCOA e.g. ePRO) and innovative study tools including our own project management tool.
e.g. Arthritis-related Pain, Bladder Pain Syndrome, Cancer Pain, Chronic Pain, Headache / Migraine, Lower Back Pain, Neuropathic Pain (diabetic, postherpetic), Postoperative Pain Management, Rheumatic Pain, Acute Postoperative / Procedural Pain
e.g. ART (IVF, ICSI), Contraception, Endometriosis, Fibromyalgia Syndrome (FMS), Obstetrics, Oncology, Pain Management, PCOS, Polymyalgia Rheumatica, Postmenopausal Complaints, Preterm labor, Rheumatoid Arthritis, Vulvar and Vaginal Atrophy, Vulvovaginal Candidiasis
e.g. Asthma (mild, moderate, severe, paediatric), Asthma / COPD Overlap Syndrome (ACOS), Chronic Obstructive Pulmonary Disease (COPD), Community-Acquired Pneumonia (CAP), COVID-19, Respiratory Virus Infection (including paediatric)
e.g. Alzheimer’s Disease, Bipolar Disorder, Depression, Epilepsy (including paediatric), Mania, Multiple Sclerosis, Narcolepsy, Parkinson’s Disease, Sensorineural Disorder
e.g. Community-acquired pneumonia (CAP), COVID-19, GI and Intra-Abdominal Infections, Immune-Modulator to prevent SARS-CoV Complication, Respiratory Virus Infections (including paediatric)
e.g. Cell and Gene Therapies, Early-Phase Clinical Development of ATMPs, Immunotherapy, Personalized Therapies, Regenerative Medicine
e.g. acute myocardial infarction, hypertension, peripheral arterial disease (PAD), pulmonary arterial hypertension (PAH) and stable angina pectoris
e.g. allergy (allergic conjunctivitis/ rhinoconjunctivitis), dermatomyositis, primary immunodeficiency diseases (PIDs) and vaccination (hepatitis B, influenza, rabies, tuberculosis)
e.g. acute porphyria and type 1 diabetes
e.g. hematological malignancy, liver cancer, metastatic breast cancer, metastatic lung tumor, non-Hodgkin lymphoma, prostatic cancer, renal cancer, schwannoma resection, solid tumors, unresectable cholangiocarcinoma and urinary bladder cancer
e.g. caries prophylaxis
e.g. alopecia areata, hypertrophic scars and psoriasis
e.g. acute porphyria, hormone replacement therapies in women, type 1 diabetes and vitamin D deficiency
e.g. acute porphyria, cholecystectomy, colitis ulcerosa, constipation, fat absorption in HIV-infected patients, inflammatory bowel disease (IBD), intra-abdominal infections, irritable bowel syndrome (IBS), liver disease, cholecystectomy and unresectable cholangiocarcinoma
e.g. hepatitis B vaccination, hepatic impairment, liver cancer and liver disease
e.g. Alzheimer’s, asthma, colitis ulcerosa, osteoarthritis, Parkinson’s Disease, polymyalgia rheumatica (PMR), psoriasis and rheumatoid arthritis
e.g. allergic conjunctivitis, keratoconjunctivitis and retinopathy
e.g. acute porphyria, juvenile dermatomyositis, polymyalgia rheumatica (PMR), pulmonary arterial hypertension (PAH) and sudden sensorineural hearing loss (SSNHL)
e.g. cartilage defects, open Gustilo-Anderson grade IIIa/IIIb tibia shaft fractures and osteoarthritis
e.g. acute peripheral vertigo, acute sensorineural hearing loss (ASNHL), rhinoconjunctivitis and sudden sensorineural hearing loss (SSNHL)
e.g. bladder pain syndrome, prostatic cancer, renal cancer, renal dysfunction / failure
and urinary bladder cancer
e.g. hepatitis B, influenza, rabies and tuberculosis
